全文获取类型
收费全文 | 529篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 11篇 |
妇产科学 | 6篇 |
基础医学 | 50篇 |
口腔科学 | 5篇 |
临床医学 | 68篇 |
内科学 | 127篇 |
皮肤病学 | 8篇 |
神经病学 | 23篇 |
特种医学 | 19篇 |
外科学 | 107篇 |
综合类 | 4篇 |
预防医学 | 25篇 |
眼科学 | 18篇 |
药学 | 32篇 |
中国医学 | 1篇 |
肿瘤学 | 48篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 23篇 |
2020年 | 12篇 |
2019年 | 15篇 |
2018年 | 15篇 |
2017年 | 8篇 |
2016年 | 17篇 |
2015年 | 25篇 |
2014年 | 18篇 |
2013年 | 25篇 |
2012年 | 47篇 |
2011年 | 37篇 |
2010年 | 16篇 |
2009年 | 23篇 |
2008年 | 29篇 |
2007年 | 31篇 |
2006年 | 31篇 |
2005年 | 30篇 |
2004年 | 35篇 |
2003年 | 32篇 |
2002年 | 23篇 |
2001年 | 2篇 |
1999年 | 1篇 |
1998年 | 4篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1976年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1956年 | 1篇 |
排序方式: 共有554条查询结果,搜索用时 15 毫秒
1.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
2.
Dany Anglicheau Alexandre Lautrette Catherine Scieux Martin Flamant Frédéric Morinet Christophe Legendre 《Nephrology, dialysis, transplantation》2003,18(8):1654-1656
BACKGROUND: Routine cytomegalovirus (CMV)-pp65 antigenaemia monitoring shows that some patients will develop pp65 antigenaemia during valaciclovir prophylaxis or after cessation of treatment. The aim of this pilot study was to evaluate the safety and efficacy of lowering immunosuppression in kidney transplant recipients who exhibit mildly symptomatic CMV infections while on valaciclovir prophylaxis. METHODS: We selected 12 patients who experienced mildly symptomatic CMV infections defined as a positive CMV-pp65 antigenaemia test associated with either neutropenia, asthenia or arthralgia, but no fever. All of them received prophylaxis with valaciclovir for at least 3 months. Testing for CMV-pp65 antigenaemia was performed weekly for 6 months. RESULTS: The mildly symptomatic infections occurred at a median interval of 69 days after transplantation-during prophylaxis in eight cases and after valaciclovir discontinuation in the other four cases. All of them were effectively managed by lowering immunosuppressive therapy, leading to the disappearance of symptoms and CMV antigenaemia reduction. No immunological complication or recurrence of CMV infection or disease was noted. I.v. ganciclovir never became necessary. CONCLUSION: The mildly symptomatic CMV infections occurring in valaciclovir-treated patients may be managed efficiently and without immunologic complication by lowering immunosuppressive therapy. 相似文献
3.
Gastrointestinal stromal tumors (GISTs)--the Lebanese experience 总被引:1,自引:0,他引:1
Salamoun W El Hajj G Aftimos G Moukharbel N Khairallah S Bejjani N Abou Sleiman CH Abou Atmeh J Azar H Elias E Abi Gerges D 《Molecular immunology》2003,39(17-18):1129-1132
4.
5.
6.
Nathalie Chavarot Gillian Divard Anne Scemla Lucile Amrouche Olivier Aubert Marianne Leruez-Ville Marc O. Timsit Claire Tinel Julien Zuber Christophe Legendre Dany Anglicheau Rebecca Sberro-Soussan 《American journal of transplantation》2021,21(7):2448-2458
Belatacept may increase cytomegalovirus (CMV) disease risk after conversion from CNI-based therapy. We analyzed CMV disease characteristics after belatacept conversion. Propensity score matching was used to compare CMV disease incidence in belatacept- and CNI-treated kidney transplant recipients (KTRs). CMV disease characteristics and risk factors under belatacept were analyzed. In total, 223 KTRs (median age [IQR] 59.2 years [45.4–68.5]) were converted to belatacept (median of 11.5 months [2.5–37.0] post-transplantation); 40/223 (17.9%) developed CMV disease. Independent risk factors included increased age (p = .0164), D+/R− CMV serostatus (p = .0220), and low eGFR at conversion (p = .0355). Among 181 belatacept-treated patients matched to 181 controls, 32/181 (17.7%) experienced CMV disease (vs. 5/181 controls [2.8%]). CMV disease cumulative incidences were 6.33 and 0.91/100 person-years (p-y) in belatacept and control groups, respectively. CMV disease risk was particularly high in elderly patients (converted >70 years) and those with eGFR <30 ml/min; cumulative incidences were 18.4 and 5.2/100 p-y, respectively. CMV diseases under belatacept were atypical, with late-onset disease (24/40 patients [60%]), high CMV seropositivity (27/40, 67%), increased severe and tissue-invasive disease rates (gastrointestinal involvement in 32/40 [80%]) and life-threatening diseases (4/40 [10%]). These findings should stimulate further research to secure the use of belatacept as a valuable rescue therapy in KTRs. 相似文献
7.
Guruprasada Shetty K Shreedhara Avabratha Seema Gonsalves Aby Dany B Sanjeev Rai 《亚太热带病杂志(英文版)》2012,2(2):107-109
ObjectiveTo study the occurrence and severity of thrombocytopenia in children with malaria.MethodsIt was a retrospective study, done at Fr Muller Medical College Hospital Mangalore, in Karnataka, India. Data regarding all positive cases of malaria < 15 years admitted in the hospital between January 2010 to June 2011 were obtained. Patients were further assessed for thrombocytopenia and its severity. Data were analysed by Chi square test using SPSS version 13.0.ResultsA total of 159 cases were included in the study with a mean age of presentation of 9 years. Plasmodium vivax was identified in 106 (66%) patients while Plasmodium falciparum in 26 (16%) and mixed infection in 27 (18%) patients. Thrombocytopenia was observed in 113 (71%) cases, of which 35 (31%) cases had mild, 49 (43%) cases moderate and 29 (26%) cases had severe thrombocytopenia. Thrombocytopenia was equally found in vivax and falciparum infection with no significant difference in severity between vivax and falciparum species.ConclusionsThrombocytopenia is frequently seen in malaria and it is not dependent on type of malaria. In any acute febrile illness, thrombocytopenia should alert one to the possibility of malaria. 相似文献
8.
9.
François Barbier Sébastien Bailly Carole Schwebel Laurent Papazian Élie Azoulay Hatem Kallel Shidasp Siami Laurent Argaud Guillaume Marcotte Benoît Misset Jean Reignier Michaël Darmon Jean-Ralph Zahar Dany Goldgran-Toledano Étienne de Montmollin Bertrand Souweine Bruno Mourvillier Jean-François Timsit for the OUTCOMEREA Study Group 《Intensive care medicine》2018,44(5):616-626
Purpose
To investigate the clinical significance of infection-related ventilator-associated complications (IVAC) and their impact on carbapenem consumption in mechanically ventilated (MV) patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLE).Methods
Inception cohort study from the French prospective multicenter OUTCOMEREA database (17 ICUs, 1997–2015) including all ESBLE carriers (systematic rectal swabbing at admission then weekly and/or urinary or superficial surgical site colonisation) with MV duration?>?48 h and?≥?1 episode of IVAC after carriage documentation. All ICU-acquired infections were microbiologically documented.Results
The 318 enrolled ESBLE carriers (median age 68 years; males 67%; medical admission 68%; imported carriage 53%) experienced a total of 576 IVAC comprising 361 episodes (63%) without documented infection, 124 (21%) related to infections other than ventilator-associated pneumonia (VAP), 73 (13%) related to non-ESBLE VAP and 18 (3%) related to ESBLE VAP. Overall, ESBLE infections accounted for only 43 episodes (7%). Carbapenem exposure within the preceding 3 days was the sole independent predictor of ESBLE infection as the causative event of IVAC, with a protective effect (adjusted odds ratio 0.2, 95% confidence interval 0.05–0.6; P?<?0.01). Carbapenems were initiated in 9% of IVAC without infection, 15% of IVAC related to non-VAP infections, 42% of IVAC related to non-ESBLE VAP, and 56% of IVAC related to ESBLE VAP (ESBLE VAP versus non-ESBLE VAP: P?=?0.43).Conclusions
IVAC in ESBLE carriers mostly reflect noninfectious events but act as a strong driver of empirical carbapenem consumption. ESBLE infections are scarce yet hard to predict, strengthening the need for novel diagnostic approaches and carbapenem-sparing alternatives.10.